# CordenPharma invests €900M in peptide production expansion

CordenPharma announced a €900 million investment over three years to expand its peptide technology platform, including new facilities in the US and Europe and a GMP capacity expansion at its Frankfurt site. The Frankfurt expansion is expected to be operational in Q4 2024.

- Type: Investment
- Announced: 2024-07-16
- Where: Frankfurt, Germany, Germany
- Value: $990.0M (900.0M EUR)
- Starts operating: Q4 2024
- Status: under construction
- Capacity: 1000 m2 of manufacturing space
- Products: peptide APIs
- Sectors: [Specialty Chemicals](https://endata.com/sectors/specialty-chemicals.md)

## Companies

- [CordenPharma](https://endata.com/companies/80892.md)

## Sources

- [cordenpharma.com](https://cordenpharma.com/articles/cordenpharma-invests-in-end-to-end-supply-expansions-across-six-technology-platforms/), 2024-11-11: "On 16 July 2024 we announced our largest strategic investment to date to grow our Peptide technology platform with a committed spend of ~€900m over the next 3 years."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.